Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa... 50 of our PICKS of TOP Trials out of Berlin 🇩🇪 @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social

Oncology Here & NOW S2E3 in #BreastCancer with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing: ✅Current & emerging treatments ✅Patient selection ✅T-DXd + pertuzumab ✅ILD management & more @hoperugo.bsky.social @elisabettabonzano.bsky.social youtu.be/YdUX52c22Ig

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin

I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎 Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀 @myesmo.bsky.social @oncoalert.bsky.social

#ResearchHighlight In a study published in #Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota & anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality. 👇

The OncoAlert WEEKLY RoundUp 🚨 Covering TOP of the week July 11-17 www.youtube.com/watch?v=N9lO... REGISTER👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @realbowtiedoc.bsky.social @drnataliagandur.bsky.social

📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer cor2ed.com/n-connect/pr... This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only

The OncoAlert🚨NEWSLETTER ⭐️COMPLETE #ASCO25 EDITION ⭐️REGISTER 👉 oncoalert360.com 👉 buff.ly/48Xpgz0 @erikahamilton9.bsky.social @drsgraff.bsky.social @maryamlustberg.bsky.social @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @drnataliagandur.bsky.social @hoperugo.bsky.social

ECO & IPOS bring you a powerful online roundtable exploring how empathy shapes cancer care, and how we can better support the professionals delivering it. Join the discussion on 🗓️ Tuesday, 25 June at 🕓 16:00–17:30 CEST. Register now 🔗 www.europeancancer.org/events/363:y...

Are you a young oncologist attending #ASCO25? Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫 Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/... @oncoalert.bsky.social @ascocancer.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @elisaagostinetto.bsky.social‬ @erikahamilton9.bsky.social‬ @drsgraff.bsky.social‬ @elisabettabonzano.bsky.social‬

The OncoAlert🚨ROUND UP Now Out‼️ Covering May 15-22, 2025 REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/xgIw0BISCpo @elisaagostinetto.bsky.social @barbaramelao.bsky.social @elisaagostinetto.bsky.social @icromeattini.bsky.social @realbowtiedoc.bsky.social

The VJ OA Oncology Journal Club Dr. Evandro de Azambuja discussing APHINITY in #BreastCancer now on APPLE PODCASTS podcasts.apple.com/se/podcast/o... @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @icromeattini.bsky.social @maryamlustberg.bsky.social

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25 youtu.be/ydcXe_faQH0 A sub analysis was just published out on European Journal of Cancer:

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

Right before the start of #ESMOBreast25, our last article is now out in #EJC In this sub-analysis of the APHINITY trial led by @ChiaraDauccia, overweight/obesity was associated with poorer survival outcomes 50-days free access link👇🏻 authors.elsevier.com/a/1l5DL3QE--... @oncoalert.bsky.social

The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025 REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... ✅DESTINY-Breast11 Update from Industry ✅PEACE V STORM in #Prostate Cancer⛈️🕊️☢️ ✅OS🧬EGFR-mutant Advanced🫁Non-Small Cell #LungCancer Treated with 1L Osimertinib and more

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study www.thelancet.com/journals/lan... Findings provide robust evidence to guide counselling and management decisions for young BRCA carriers with prior breast cancer

NEWS FROM INDUSTRY🚨 Source AstraZeneca DESTINY-Breast11 Update DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen www.astrazeneca.com/media-centre...

Join @OncoAlert 🚨& @VJOncology Journal Club Discussing : Assisted reproductive technology in young BRCA carriers with a pregnancy after #BreastCancer podcasts.apple.com/se/podcast/o... @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @realbowtiedoc.bsky.social

Join Us at Oncology Here & Now www.oncoalert360.com/12789765039p... @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @biagioricciutimd.bsky.social @barbaramelao.bsky.social @weoncologists.bsky.social @drsgraff.bsky.social @erikahamilton9.bsky.social

I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫 Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸 @oncoalert.bsky.social

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity In this review we address this topic👇🏻 @oncoalert.bsky.social www.sciencedirect.com/science/arti...

The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025 REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/l_jcTe69cCs @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social

The #AURORA Data Analysis Committee is in Florence for a “datathon”! Over the next 2 days, PIs, bioinformaticians, clinicians, and BIG HQ are working together on analyses to advance a new AURORA manuscript. @aftimosp.bsky.social @elisaagostinetto.bsky.social

Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠 Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻 @oncoalert.bsky.social doi.org/10.1016/j.br...

Oncology HERE & NOW Webcast/Podcast Now Out JOIN Faulty 🚨 @realbowtiedoc.bsky.social 🇺🇸& @crisbergerot.bsky.social 🇧🇷 as they dive into #SupportiveCare , the future of #Telemedicine and much more! youtu.be/4WYdTostU7w

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival link.springer.com/article/10.1... Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients. @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social

Now out a new episode of Oncology Here&Now, a podcast by @oncoalert.bsky.social 🎙️ I had the pleasure to discuss with @maryamlustberg.bsky.social about adjuvant CDK4/6i, including: 🔸how to choose between abema and ribo 🔸how to manage progression during or after adj CDK4/6i 🔸Male breast cancer!

Free & On Demand Breast Cancer UPDATE Brought to you by OncoAlert & Partners DIRECT LINK/WATCH HERE👉 buff.ly/myqd20R Join the Breast Cancer Faculty @hoperugo.bsky.social @drsgraff.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social @elisaagostinetto.bsky.social

I am very proud to see published in #JCO the results of our global collaboration🌎 led by @matteolambe showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

The #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://buff.ly/4hKRVdM @FernandoOnco 🇧🇷 of Brazil Covering How I Treat #BreastCancer When I dont have the resources Log in to chat with Dr. Moura Patients living in LMICs suffers larger gaps during breast cancer, particularly in public healthcare

The OncoAlert Colloquium🚨NEXT WEEK FREE REGISTRATION HERE👉 buff.ly/3CChgre @drchoueiri.bsky.social @icromeattini.bsky.social @yukselurun.bsky.social @aftimosp.bsky.social @jrgralow.bsky.social @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @lymphomadoc.bsky.social

FDA approved Dato-DXd for HR+/HER2-neg pretreated metastatic #breastcancer based on results of Tropion-Breast01 @oncoalert.bsky.social www.fda.gov/drugs/resour...

Out in @ESMO_Open by @hoperugo.bsky.social et al real-world data on CDK4/6i in #breastcancer 🌎 No significant OS difference between 1L palbo, ribo, and abema Are CDK4/6i equal? Do OS differences in randomized trials depend on study design? @oncoalert.bsky.social www.esmoopen.com/article/S205...

🇮🇹The OncoAlert Colloquium by @oncoalert.bsky.social si avvicina! 3-9 Febbraio, 100% virtuale, interattivo e completamente gratuito. Link per registraz ⬇️ 🇧🇪🇫🇷L’OncoAlert Colloquium s’approche! Du 3 au 9 février, 100% virtuel, interactif et complètement gratuit Lien pour s’inscrire⬇️ buff.ly/3CChgre

Following the results presented at #SABCS23, the PREFERABLE-EFFECT trial is now out in @JCO_ASCO Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼‍♀️🏃🏼‍♀️‍➡️ @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

Now out in Cancer Treatment Reviews a nice review on CAR-T cell therapy for #breastcancer, a still experimental approach but with promising expectations for future development and implementation in clinical practice @oncoalert.bsky.social www.sciencedirect.com/science/arti...

Trastuzumab-pertuzumab-taxane is the SoC 1️⃣line for metastatic HER2+ breast cancer; yet, taxane may induce neurotoxicity. The EMERALD trial now out in @JCO_ASCO investigated the role of eribulin instead of a taxane in this setting ⬇️ @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

The OncoAlert Video Journal: "Deep Learning Model for Predicting Immunotherapy Response in Advanced #NSCLC Non−Small Cell #LungCancer 🫁" This Week @biagioricciutimd.bsky.social 🇺🇸of @danafarbernews.bsky.social Guides us through his paper out on JAMA oncology www.youtube.com/watch?v=LuD4...

In an exploratory analysis of the #PALLAS trial, @elisaagostinetto.bsky.social et al. 💡explored impact of concomitant use palbociclib 💊with PPIs on survival outcomes 📊in #breastcancer . Read more in @ESMO_Open 👇🏻 sciencedirect.com/science/articl… @oncoalert.bsky.social #Oncologygy

Today the Office of the US Surgeon General advisory released a report on Alcohol and Cancer Risk 🍷 Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer @oncoalert.bsky.social www.hhs.gov/surgeongener...

At #SABCS24 the updated survival results of the OLYMPIA trial were presented @FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️ @oncoalert.bsky.social medimix.be/onco/sabcs-s...

Join OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer #SABCS24 Link to view: https://buff.ly/4iSMoU6 Dr. @elisaagostinetto.bsky.social interviews Dr. Souza, discussing the safety and impact of this therapy.

What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊 Can PPI use explain why the PALLAS trial was negative? Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻 @oncoalert.bsky.social www.sciencedirect.com/science/arti...

Happy New Year from OncoAlert @elisaagostinetto.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social @realbowtiedoc.bsky.social @yukselurun.bsky.social @drchoueiri.bsky.social @barbaramelao.bsky.social @jameabraham.bsky.social @drsanjaypopat.bsky.social @drsgraff.bsky.social

Also at Christmas.. the @oncoalert.bsky.social newsletter is out!!!🎄✨ Register at Oncoalert360.com to receive it in your inbox 📥

Dear Colleagues, Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨 @elisaagostinetto.bsky.social @drjnaidoo.bsky.social @lymphomadoc.bsky.social @realbowtiedoc.bsky.social @stephenvliu.bsky.social @drlestercoll.bsky.social @erikahamilton9.bsky.social

The OncoAlert🚨 Network along with our partners at @ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg invite you to the Colloquium Register for FREE HERE: https://buff.ly/3CChgre The Best in Oncology 2024, One week review focus on practice changing data

At #SABCS24 I discussed with @VJOncology the results of DECRESCENDO, our investigator-initiated clinical trial of chemotherapy de-escalation in HER2+ early breast cancer @oncoalert.bsky.social www.vjoncology.com/video/xbqqwr...